During the past decade, Texas Cancer Center-Sherman conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 21 clinical trials were completed, i.e. on average, 350% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 8 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Cancer Center-Sherman" #1 sponsor was "US Oncology Research" with 9 trials, followed by "Bristol-Myers Squibb" with 5 trials sponsored, "Radiation Therapy Oncology Group" with 4 trials sponsored, "NSABP Foundation Inc" with 2 trials sponsored and "Novartis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Cancer Center-Sherman" #1 collaborator was "National Cancer Institute (NCI)" with 8 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Texas Cancer Center-Sherman" are "Breast Cancer" (4 trials), "Metastatic Breast Cancer" (4 trials), "Prostate Cancer" (4 trials), "Non-Small Cell Lung Cancer" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Texas Cancer Center-Sherman" in a lesser frequency.

Most popular intervention types in "Texas Cancer Center-Sherman" are "Drug" (28 trials), "Radiation" (7 trials), "Other" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (6 trials), "Nivolumab" (5 trials), "Paclitaxel" (5 trials), "Docetaxel" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Cancer Center-Sherman" are 18 trials for "All" genders, 7 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Cancer Center-Sherman". undefined are not yet recruiting, 1 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Texas Cancer Center-Sherman, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Cancer Center-Sherman, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".